Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics, Dualsystems to Co-Market Yeast Two-Hybrid Screens for Membrane Proteins

NEW YORK (GenomeWeb News) – Hybrigenics said today that it has signed a co-marketing agreement with Dualsystems Biotech covering yeast two-hybrid screening services for full membrane proteins.
 
Under the terms of the agreement, both Dualsystems and Hybrigenics will commercialize Dualsystems’ DUALmembrane screens, which were designed for identifying protein interactions involving full membrane proteins.
 
Hybrigenics will perform the screens on its ISO 9001-certified yeast two-hybrid platform.
 
The companies said that the profit-sharing partnership will “boost Dualsystems' commercial and production volumes for its membrane technology.”
 
Hybrigenics is a biopharmaceutical company focused on developing cancer therapies through its Hybrigenics Pharma unit. The company also offers a range of protein-interaction screening services.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.